Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — ...

显著降低发作性睡病（narcolepsy）患者的猝倒发作（cataplexy attacks）频率。AXS-12是一种高选择性的强效去甲肾上腺素再摄取抑制剂及皮质多巴胺调节剂。

(CNN) — Matthew Horsnell began falling asleep for no reason when he was in sixth grade. “I would go to bed at 8:30 at night, yet every morning I would wake up and struggle to get out of bed ...

In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...

Gelastic cataplexy is a sudden loss of muscle tone without loss of consciousness triggered by laughter. It’s a characteristic sign of a rare genetic disease called Niemann Pick disease type C.

ENCORE was a multi-center, two-period Phase 3 trial evaluating the long-term efficacy and safety of AXS-12 in patients with narcolepsy with cataplexy, consisting of a 6-month open-label AXS-12 ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and ...

About LUMRYZ™ (sodium oxybate) for extended-release oral suspension LUMRYZ is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime ...